Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 28969054
Nguyen HT, Kugler JM, Loya AC, Cohen SM (2017) USP21 regulates Hippo pathway activity by mediating MARK protein turnover. Oncotarget 8, 64095-64105 28969054
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.

K783-ub - MARK1 (human)
Modsite: SGTSIAFkNIAsKIA SwissProt Entrez-Gene
Orthologous residues
MARK1 (human): K783‑ub, MARK1 iso3 (human): K746‑ub, MARK1 (mouse): K783‑ub, MARK1 (rat): K781‑ub
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
DEUBIQUITINASE USP21 (human) co-immunoprecipitation, siRNA inhibition of enzyme, transfection of wild-type enzyme, transfection of inactive enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA increase siRNA for USP21 increases ubiquitination
Downstream Regulation
Effect of modification (function):  protein stabilization
Effect of modification (process):  transcription, induced